{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["durvalumab","tremelimumab"]],"indication":"locally advanced renal cell carcinoma","name":"NCT02762006","nct_id":"NCT02762006","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02762006. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Following systemic therapy, patients will undergo nephrectomy. Adjuvant therapy will be administered within 4-6 weeks of surgery. Subsequent follow-up will then be completed to assess adverse event resolution and long-term outcomes.\n\n* Cohort 1: Durvalumab x 1 dose (n=6)\n* Cohort 2: Durvalumab + Tremelimumab x 1 dose (n=6)\n* Cohort 2a: Durvalumab + Tremelimumab x 1 dose (n=12)\n* Cohort 3: Durvalumab + Tremelimumab x 1 dose (n=9)\n\nCohorts 1 and 2: Adjuvant dosing of Durvalumab x 1 beginning 2-8 weeks after surgery.\n\nCohort 2a: Durvalumab monotherapy until 1 year after nephrectomy.\n\nCohort 3: Adjuvant dosing of durvalumab + tremelimumab x 1 beginning 2-8 weeks after surgery, then durvalumab monotherapy until 1 year after nephrectomy.","label":"Durvalumab + Tremelimumab with Nephrectomy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2020-11-06","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma","Kidney Cancer"],"enrollment":{"count":29,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Tremelimumab","otherNames":[],"type":"DRUG"}],"last_update":"2024-03-18","lead_sponsor":"Moshe Ornstein","official_title":"A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2020-11-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Patients with Dose Limiting Toxicity (DTL)","timeFrame":"Up to 12 months after screening"}],"references":[],"start_date":{"date":"2016-12-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT02762006"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02762006"}